...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology research: the official journal of the Japan Society of Hepatology >Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients.
【24h】

Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients.

机译：金刚烷胺和干扰素的总和治疗丙型肝炎病毒的老人病人。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Treatment of hepatitis C virus (HCV) infection with interferon (IFN) in older patients may not be feasible on account of side effects: we, therefore, attempted combined treatment with amantadine hydrochloride (AH) in order to improve not only the flu-like symptoms associated with IFN but also the anti-viral effect. Methods: Patients over 65 years of age, (n=165), who had failed to eradicate HCV infection after previous treatment with IFN were randomized into three groups and treated for 12 months, group A received AH 100 mg twice per day; group B received IFNalpha-n(3) 6 M units every other day for 3 months followed by 3 MU and group C the same dose of IFNalpha-n(3), as in B, and AH 200 mg per day. Results: Group A, 42 patients agreed to undergo treatment (genotype 1b n=39); at the end of treatment 21 patients (50%) had normal ALT and seven (17%) negative polymerase chain reaction (PCR). HCV-RNA was not detectable in seven patients at the sixth month follow-up and in six (14%) after 23plus minus2 months. Group B, 39 patients accepted the treatment (genotype 1b n=31); at the end of treatment, 17 patients (44%) had normal ALT and 13 negative PCR (13%). HCV-RNA was not detectable in nine patients (23%) at the sixth month of follow-up and in eight (21%) after 22plus minus4 months. Group C, 38 patients accepted the treatment (genotype 1b n=32); at the end of treatment, 20 (53%) patients had normal ALT and 15 negative PCR (39%). HCV-RNA was not detectable in 15 patients at the sixth month follow-up and in 11 after 21plus minus4 months (29%). Forty-six patients did not accept the scheme of treatment and 26 of them had a follow-up of 20plus minus3 months. HCV-RNA copies and prevalence of genotype 1b were comparable to the treated groups: HCV-RNA was fluctuating or unchanged during the entire follow-up. Conclusions: AH associated with IFN was able to improve the negativization of HCV-RNA and sustained response to IFN and decreased the malaise associated with IFN; an increase in viral copies was observed under AH in about 40%.
机译：背景:治疗丙型肝炎病毒(HCV)干扰素(IFN)在老年患者感染可能不是可行的副作用:因此,我们试图结合治疗金刚烷胺盐酸盐(啊)为了提高不仅带来的流感样症状干扰素还抗病毒的效果。患者超过65岁,(n = 165)前一后未能根除丙肝病毒感染用干扰素治疗被随机分配到三个组和治疗12个月,A组收到啊100毫克每天两次;收到IFNalpha-n(3) 6台每隔一天3个月3μ和C组紧随其后相同剂量的IFNalpha-n(3),在B, 200啊毫克/天。接受治疗(基因型1 b n = 39);结束治疗的21例患者(50%)有正常的ALT和7 -聚合酶链(17%)反应(PCR)。第六个月随访和七个病人在六23 + minus2个月后(14%)。39岁的患者接受了治疗(基因型1 bn = 31);有正常的ALT和13 - PCR(13%)。没有检测到9名患者(23%)在吗第六个月的随访,8例(21%)22 + minus4月。接受了治疗(基因型1 b n = 32);结束治疗,20例(53%)患者正常ALT和15 - PCR(39%)。在15例检测到第六个月后续在21 + minus4后11个月(29%)。治疗方案和26人后续的20 + minus3月。和流行的基因型1 b相比治疗组:HCV-RNA波动或在整个后续不变。结论:与干扰素能相关啊提高negativization HCV-RNA和持续的对干扰素和减少了困境与干扰素;观察下副本啊在40%左右。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号